NCT00396006View on ClinicalTrials.gov

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 27, 2006

Primary Completion Date

December 14, 2007

Study Completion Date

December 14, 2007

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions

BIOLOGICAL

Alpha1-Proteinase Inhibitor

60 mg/kg, weekly, intravenous infusion

Trial Locations (5)

Unknown

Adelaide

Melbourne

Nedlands

Otahuhu

Hamilton

All Listed Sponsors

lead

Baxalta now part of Shire

INDUSTRY

NCT00396006 - Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) | Biotech Hunter | Biotech Hunter